Macomics teams up with the Swiss cancer institutecancer institute to develop macrophage therapies
AACR
Macomics partnered with the Institute of Oncology Research (IOR) to test the former’s macrophage-targeted therapies in the latter’s mouse models of prostate cancer.
“Macrophages are key to multiple diseases of high unmet medical need, including as key mediators of solid tumour immunosuppression,” Macomics CEO Stephen Myatt said. “This collaboration enhances further our ability to explore and exploit macrophage biology for the development of novel therapeutic approaches.”
IOR’s mouse models of prostate cancer are specifically designed to feature the fundamental role of myeloid cells in tumour progression and are based on the institute’s “deep understanding of molecular mechanisms in cancer development,” said Andrea Alimonti, the director of IOR.
The partners will test and characterise Macomic’s macrophage-targeting drug candidates, which feature novel mechanisms of action.
Macrophage target discovery
Macomics’ pipeline of preclinical macrophage-targeting antibodies was built using its ENIGMAC platform, which combines patient datasets, macrophage cell models, and gene editing capabilities to discover new disease-specific macrophage targets.
The biotech shared early mechanistic and in vivo data for its lead cancer programme, a ligand independent-pan-LILRB antibody, at the American Association for Cancer Research meeting earlier this year. The results suggest MACO-355 can mediate macrophage reprogramming under immunosuppressive conditions.
Macomics is also working with the AIRC Institute of Molecular Oncology in Italy to characterise its macrophage-directed therapies with the research organisation’s ex vivo tumoroid models.
Separately, Ono Pharmaceutical has an exclusive option to license from Macomics an immuno-oncology candidate directed against a novel macrophage target.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.